Guardant Health (FRA:5GH) NonCurrent Deferred Liabilities: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5GH Guardant Health Inc FRA:5GH
65 GF Score
Price €125.88
GF Value €50.99
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health NonCurrent Deferred Liabilities?

Guardant Health FRA:5GH +1.06% 65 NonCurrent Deferred Liabilities is €0 Mil as of Jun. 2026. GuruFocus rates FRA:5GH with a GF Score™ of 65/100 and a GF Value™ of €50.99 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Guardant Health's non-current deferred liabilities for the quarter that ended in Jun. 2026 was €0 Mil.

Guardant Health NonCurrent Deferred Liabilities Related Terms

Guardant Health NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Guardant Health's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health NonCurrent Deferred Liabilities Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Guardant Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:5GH
65GF Score
Guardant Health Inc FRA:5GH
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0 Mil mean?
Guardant Health (FRA:5GH) has a NonCurrent Deferred Liabilities of €0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Guardant Health and its competitors.
Is Guardant Health's NonCurrent Deferred Liabilities too high?
Guardant Health's current NonCurrent Deferred Liabilities is €0 Mil. Overall, Guardant Health has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's NonCurrent Deferred Liabilities compare to MEDP and LH?
Guardant Health's NonCurrent Deferred Liabilities of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Guardant Health and its competitors. Guardant Health's current NonCurrent Deferred Liabilities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (FRA:5GH) is currently considered Significantly Overvalued. The stock's GF Value™ is €50.99, compared to a current price of €125.88 — trading 146.9% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0 Mil. Guardant Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Guardant Health (FRA:5GH), the current NonCurrent Deferred Liabilities is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €125.88 is trading 146.9% above its estimated GF Value™ of €50.99. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • NonCurrent Deferred Liabilities: €0 Mil
  • GF Value™: €50.99 vs. price of €125.88 (146.9% above fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
65GF Score

Get the complete analysis for FRA:5GH

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€125.88
Price
€50.99
GF Value